Cor Vasa 2018, 60(6):e597-e602 | DOI: 10.1016/j.crvasa.2017.12.012
Atrial fibrillation, oral anticoagulants and health related quality of life
- a Riga Stradins University, Faculty of Medicine, Latvia
- b Riga Stradins University, Department of Internal Diseases, Latvia
- c Riga Stradins University, Division of Doctoral Studies, Latvia
Introduction: Atrial fibrillation (AFib) is a disease that can influence the health related quality of life. Also oral anticoagulants can influence it both because of its therapeutic benefits or complications as well as how the anticoagulant usage influence the person's life style by regular laboratory test necessity or diet restrictions.
Aim: Determine and analyze whether there is a statistically significant difference comparing health related quality of life between K vitamin antagonist, warfarin, users, novel anticoagulant (NOAC), rivaroxaban, dabigatran, users and patients, who do not use any kind of oral anticoagulant.
Materials and methods: A cross-sectional analytic research was made in Pauls Stradins Clinical university hospital, Center of Cardiology in Riga, Latvia during the time period from October 2016 till June 2017. Persons with high-risk non-valvular atrial fibrillation were offered to participate in this research. If the person agreed, an oral interview with questions about disease anamnesis, demographic data, laboratory test results, echocardiography results, modified SF-36 survey, used oral anticoagulant type was held. Data were precised with the help of the case anamnesis information. For statistical data analysis were used SPSS Statistics database.
Results: Altogether 218 patients were enrolled, of which 56.9% were female and 43.1% - male, mean age - 70.4 years, mean CHA2D2-VASc score - 4.4. Warfarin used 37.6%, 33.0% - novel oral anticoagulants, but 29.4% did not use any kind of oral anticoagulant. A statistically significant difference was discovered between the mean ranks in physical functioning sections comparing warfarin (mean rank 95.85) with NOACs (mean rank 124.57); p = 0.012. Also a statistically significant difference was in social functioning comparing warfarin (mean rank 96.16) with NOACs (mean rank 119.08); p = 0.026. Age had low negative correlation (r = -0.23) with physical functioning. Duration of atrial fibrillation diagnosis did not have correlations with the results.
Conclusion: NOAC usage correlates with the best health related quality of life scores, gaining a statistically significant difference compared to warfarin users in physical functioning (warfarin - 95.85, NOACs - 124.57; p = 0.012) and social functioning mean ranks (warfarin - 95.16, NOACs - 119.08; p = 0.026). Age had low negative correlation with physical functioning scores.
Keywords: Atrial fibrillation; Dabigatran; Oral anticoagulants; Quality of life; Rivaroxaban; Warfarin
Revised: December 20, 2017; Accepted: December 23, 2017; Published: December 1, 2018 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- C.A. Sanoski, Clinical, economic, and quality of life impact of atrial fibrillation, Journal of Managed Care & Specialty Pharmacy 15 (6 Suppl. B) (2009) 4-9.
Go to original source...
- A. Hansson, B. Madsen-Härdig, S.B. Olsson, Arrhythmia-provoking factors and symptoms at the onset of paroxysmal atrial fibrillation: a study based on interviews with 100 patients seeking hospital assistance, BMC Cardiovascular Disorders 4 (2004) 13.
Go to original source...
Go to PubMed...
- G.Y.H. Lip, Mechanisms of Thrombogenesis in Atrial Fibrillation. Up to Date. Retrieved 6 July 2017, from http://www.uptodate.com/contents/mechanisms-of-thrombogenesis-in-atrial-fibrillation.
- M. Pirmohamed, Warfarin: almost 60 years old and still causing problems, British Journal of Clinical Pharmacology 62 (2006) 509-511.
Go to original source...
Go to PubMed...
- R.G. Hart, L.A. Pearce, M.I. Aguilar, Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation, Annals of Internal Medicine 146 (2007) 857-867.
Go to original source...
- D. Nguyen-Khoa, Vitamin K Deficiency Treatment & Management, Medscape. Retrieved 10 July 2017, from http://emedicine.medscape.com/article/126354-treatment#d9.
- L.E. Rohde, M.C. de Assis, E.R. Rabelo, Dietary vitamin K intake and anticoagulation in elderly patients, Current Opinion in Clinical Nutrition and Metabolic Care 10 (2007) 1-5.
Go to original source...
Go to PubMed...
- Dabigatran, European Medicines Agency. Retrieved 5 July 2017, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000829/human_med_000981.jsp
- Rivaroxaban, European Medicines Agency. Retrieved 5 July 2017, from http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp∣=WC0b01ac058001d124
- J. Shin, A. Secora, J. Coresh, et al., Abstract P255: use of novel oral anticoagulants among patients with atrial fibrillation increased even in those with severely impaired kidney function, Circulation 135 (2017) 255.
Go to original source...
- H. Heidbuchel, P. Verhamme, M. Alings, et al., European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace 15 (2013) 625-651.
Go to original source...
Go to PubMed...
- C.T. Ruff, R.P. Giugliano, E. Braunwald, et al., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials, Lancet 383 (2014) 955-962.
Go to original source...
Go to PubMed...
- P. Kirchhof, S. Benussi, D. Kotecha, et al., 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, European Heart Journal 37 (2016) 2893-2962.
Go to original source...
Go to PubMed...
- J.M. Alegret, X. Vinolas, M.A. Arias, et al., New oral anticoagulants vs vitamin K antagonists: benefits for health-related quality of life in patients with atrial fibrillation, International Journal of Medical Sciences 11 (2014) 680-684.
Go to original source...
Go to PubMed...
- B.U. Monz, S.J. Connolly, M. Korhonen, et al., Assessing the impact of dabigatran and warfarin on health-related quality of life: results from an RE-LY sub-study, International Journal of Cardiology 168 (October (3)) (2013) 2540-2547.
Go to original source...
Go to PubMed...
- E. Marquez-Contreras, N. Martell-Claros, V. Gil-Guilen, et al., Quality of life with rivaroxaban in patients with non-valvular atrial fibrilation by therapeutic compliance, Quality of Life Research 26 (2017) 647-654.
Go to original source...
Go to PubMed...
- T.R. Lancaster, D.E. Signer, M.A. Sheehan, et al., The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Internal Medicine Journal 151 (1991) 1944-1949.
Go to original source...
Go to PubMed...
- A.K. Das, A. Ahmed, O.J. Corrado, R.M. West, Quality of life of elderly people on warfarin for atrial fibrillation, Age and Ageing 38 (2009) 751-754.
Go to original source...
Go to PubMed...
- J.B. Borges, R.T. Barros, S.M. Carvalho, M.A. Silvia, Correlation between quality of life, functional class and age in patients with cardiac pacemaker, Revista Brasileira de Cirurgia Cardiovascular 28 (2013) 47-53.
Go to original source...
Go to PubMed...